Visualizing Health Policy: Recent Trends in Prescription Drug Costs
This Visualizing Health Policy infographic with JAMA spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices.
View the Latest: Prices
Filter
-
-
What are the recent and forecasted trends in prescription drug spending?
FeatureThis slideshow looks at past, present and future trends in prescription drug spending with a focus on the role of specialty drugs.
-
Web Event: Rx Drugs and the U.S. Health System – A Conversation About Drug Prices
Event Date:EventThe Kaiser Family Foundation will host a web conversation to discuss the drivers of recent and forecasted trends in prescription drug spending and examine how drug prices are set.
-
Why are Healthcare Prices So High, and What can be Done about Them?
Event Date:EventAn archived webcast of this forum is now available at www.healthsystemtracker.org . Nearly a fifth of the United States’ economy goes to healthcare spending – a far larger share than in any other large, wealthy country in the world.
-
How Do Health Care Prices and Utilization in the United States Compare to Peer Nations?
Issue BriefThis updated chart collection compares indicators of health care utilization and prices in the United States and 11 similarly wealthy countries to investigate whether higher prices or higher utilization of health care services drives the high health care expenditures in the U.S. relative to peer nations.
-
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act
Issue BriefThe Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
-
Analysis Examines the Implications of Price Transparency for Providers and Patients as New Rules Go into Effect
News ReleaseA new KFF analysis examines how new federal rules on price transparency for health services may affect patient decision-making and market pricing. As of January 1, 2021, the United States Department of Health and Human Services requires that hospitals publish payer-negotiated rates for common services on their websites.
-
How Do Prescription Drug Costs in the United States Compare to Other Countries?
FeatureThis chart collection examines what we know about prescription drug spending and use in the U.S. and comparably large and wealthy countries, using data from the Organization for Economic Cooperation and Development (OECD).
-
Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020
Issue BriefRecent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.
-
Half of All Hospitals Have Charity Care Costs That Represent 1.4% or Less of Their Operating Expenses
News ReleaseHalf of hospitals reported that the cost of providing charity care to patients represented 1.4% or less of their operating expenses in 2020, though the rates vary widely from hospital to hospital, a new KFF analysis finds.